Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps

Brussels, Belgium – 10 June 2024 – 07:00 AM CET– New recommendations released today in Epileptic Disorders by a global expert group comprising epileptologists, neurologists and pharmacologists from Europe and North America address the critical unmet needs associated with preventing progression of epileptic seizures to more severe and complex types that require urgent, emergency care.¹The new recommendations include a robust and uniform definition framework for different types of seizures ranging from prolonged seizures to status epilepticus, as well as recommending treatment as early as possible to prevent progression to seizure emergencies.¹ Until now no international evidence-based clinical definitions existed to support decision-making.¹ 

Although there have been significant advancements in epilepsy treatment, including the availability of an increased number of chronic anti-seizure medications (ASMs), the reality remains that 30–40% of patients still do not achieve freedom from seizures.^1,2,3  Uncontrolled seizures negatively impact patient and caregiver quality of life and increase the risk of injury, seizure recurrence and progression to more severe types associated with long-term serious consequences such as neuronal cell death, irreversible brain damage and death.^{1,2,3,4,5,6,7}  These individuals face the constant threat that their seizures may progress to become a seizure emergency.⁴

To address the significant unmet need, the Seizure Termination Project* has announced a novel perspective on preventing seizure emergencies, advocating for the concept of ‘rapid and early seizure termination’ or REST, aiming for treatment administration as early as possible after seizure onset.¹ This approach not only seeks to prevent the escalation of seizures but also aims to alleviate the healthcare burden by reducing the need for hospitalization.¹ This marks a significant shift in the way epilepsy is managed today, emphasizing the importance of early intervention.

“It is essential that we prevent seizures from progressing to more severe and complex types which result in significant physical, psychological, cognitive and socioeconomic burden for patients, caregivers and healthcare systems alike,” said Dr Jesus Eric Pina-Garza, Co-chair of the Seizure Termination Project and Director of Pediatric Epilepsy at Centennial Children’s Hospital, Nashville, US. “Providing a clearer picture for clinicians, patients, and caregivers, on how and when to effectively treat prolonged seizures through the introduction of the concept of REST is an important step forward in disease management which will help to facilitate improved outcomes for patients and reduce healthcare resource utilization.”

“This initiative not only shines a light on the urgent need for innovations in seizure emergency management but also offers hope for patients and caregivers looking for more control over their condition. Our goal is to ensure that every individual with epilepsy has the chance to live a life unburdened by the fear of seizure emergencies, and we are committed to advancing scientific and clinical research in this area,” said Dr Konrad Werhahn, Global Medical Affairs, UCB.

*About the Seizure Termination Project

The Seizure Termination Project is a world-renowned expert working group comprising 12 epileptologists, neurologists and pharmacologists from Europe and North America who specialize in the care of both children and adults living with epilepsy. Founded in 2022 as an independent expert group, the Seizure Termination Project was supported by UCB with a goal to facilitate better management of prolonged seizures and seizure clusters and avoid progression to a seizure emergency. 

For further information, contact UCB: 
Global Communications
Nick Francis
T +44 7769 307745
email nick.francis@ucb.com  

Corporate Communications, Media Relations
Laurent Schots 
T +32.2.559.92.64 
email Laurent.schots@ucb.com 

Investor Relations
Antje Witte   
T +32.2.559.94.14 
email antje.witte@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

Forward looking statements 
This press release may contain forward-looking statements including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems. 

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. 

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. 

References:

1. Pina-Garza JE, et al. Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher-level emergency: Consensus recommendations of an expert working group. Epileptic Disord. 2024; 00:1–14. https://onlinelibrary.wiley.com/doi/10.1002/epd2.20243.
2. Sharma S, Detyniecki K. Rescue therapies in epilepsy. Curr Opin Neurol. 2022;35(2):155-60.
3. Sultana B, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96(17):805–17.
4. Asnis-Alibozek A, Detyniecki K. The unmet need for rapid epileptic seizure termination (REST). Epilepsy Behav Rep. 2021;15:100409.
5. Shinnar S. Who is at risk for prolonged seizures? J Child Neurol. 2007;22(5 Suppl):14S-20S.
6. Naylor DE. Treating acute seizures with benzodiazepines: does seizure duration matter? Epileptic Disord. 2014;16 Spec No 1:S69-83.
7. Kortland LM, et al. Socioeconomic Outcome and Quality of Life in Adults after Status Epilepticus: A Multicenter, Longitudinal, Matched Case-Control Analysis from Germany. Front Neurol. 2017;8:507.